These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 14500835)

  • 1. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha.
    Vilain N; Tsai-Pflugfelder M; Benoit A; Gasser SM; Leroy D
    Nucleic Acids Res; 2003 Oct; 31(19):5714-22. PubMed ID: 14500835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA.
    Leroy D; Kajava AV; Frei C; Gasser SM
    Biochemistry; 2001 Feb; 40(6):1624-34. PubMed ID: 11327821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
    Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
    Dickey JS; Osheroff N
    Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-Mechanism Model for the Interaction of Etoposide Quinone with Topoisomerase IIα.
    Gibson EG; King MM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2016 Sep; 29(9):1541-8. PubMed ID: 27533850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism.
    Lindsey RH; Pendleton M; Ashley RE; Mercer SL; Deweese JE; Osheroff N
    Biochemistry; 2014 Oct; 53(41):6595-602. PubMed ID: 25280269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4,6-Substituted-1,3,5-triazin-2(1H)-ones as monocyclic catalytic inhibitors of human DNA topoisomerase IIα targeting the ATP binding site.
    Pogorelčnik B; Janežič M; Sosič I; Gobec S; Solmajer T; Perdih A
    Bioorg Med Chem; 2015 Aug; 23(15):4218-4229. PubMed ID: 26183545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
    Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
    Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
    Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
    Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
    Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
    Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
    Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
    Matsumoto Y; Kunishio K; Nagao S
    J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
    Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
    Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of multiple copies of a mutant topoisomerase IIalpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines.
    Campain JA; Slovak ML; Schoenlein PV; Popescu NC; Gottesman MM; Pastan I
    Somat Cell Mol Genet; 1995 Nov; 21(6):451-71. PubMed ID: 8600572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.